Table 4 Response to Seizure Treatment and Other Relevant Outcomes
From: A clinical trial of enteral Levetiracetam for acute seizures in pediatric cerebral malaria
Levetiracetam (n = 23) | Usual Care (n = 21) (Phenobarbital) | P-value | |
|---|---|---|---|
Minutes with seizure | p = 0.54^ | ||
mean (SD) ~ | 165 (266) | 465 (639) | |
IQR; maximum | 26–305; 563 | 42–734; 1473 | |
Status epilepticusŦ | 2 | 4 | p = 0.58 |
Periodic EEG patterns∞ | LPDs (1) GPDs (1) | BIRDS (1) LPDs (4) LRDA (2) | – |
Seizure free (n, %) | 19 (83%) | 16 (76%) | p = 0.72 RR 1.08 (95% CI 0.8–1.47) |
Required dose escalation | 4/23 (17%) | Not applicable | – |
Treatment failure, crossed over | 2 | 3 | p = 0.66 |
Safety failure* | 0 | 5 | p = 0.019# RR 0 (95% CI 0–0.59) |
Coma durationϯ (mean hours, SD) | n = 22 35.4 (29.0) | n = 16 34.6 (27.8) | p = 0.91 |
Disposition | p = 0.091 | ||
-Alive, no sequelae | 19 | 14 | |
-Sequelae | 3 | 2 | |
-Died | 1 | 5 |